Comparative Pharmacology
Head-to-head clinical analysis: PHILITH versus QUASENSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHILITH versus QUASENSE.
PHILITH vs QUASENSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.
Quetiapine antagonist at dopamine D2 and serotonin 5-HT2A receptors; also affects histamine H1 and adrenergic α1 and α2 receptors.
1 mg orally once daily
100 mg orally every 12 hours.
None Documented
None Documented
Terminal half-life 12 hours; clinically relevant for twice-daily dosing with steady state reached after 2-3 days.
Terminal elimination half-life is 8–12 hours in healthy adults; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Primarily renal excretion (approximately 70% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for about 20% (including metabolites); 10% undergoes metabolic clearance.
Category C
Category C
Oral Contraceptive
Oral Contraceptive